• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Taking a Platform Approach to Drug Pricing Issues Can Help Unify Adversarial Sides

by David de Vogel, Founder & CTO at Kalderos 10/05/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
David de Vogel, Founder & CTO at Kalderos

Healthcare is a notoriously complex industry with a multitude of stakeholders, many of whom find themselves in adversarial positions, simply due to the way the market operates. Ultimately, there is a shared goal of providing the best care to the patient. But as stakeholder relationships grow more complex, there can also be conflicts that drive wedges between parties and hamper successful collaboration.

We see this dynamic playing out in many areas of healthcare, but particularly in drug pricing, where conflicts over reimbursement, contracting and drug costs have been especially apparent over the past few years.

HIT platforms have shown they can help. In a number of arenas, HIT platforms are serving as independent arbiters of thorny healthcare issues, by enabling formerly antagonistic parties to operate using a single set of trustworthy data. One example is electronic prescription platforms, which provide an independent mediator to ensure prescription safety, security and legitimacy. Another example is interoperability platforms, which have played key roles in bringing transparency to payers and providers in the application of value-based payment contracts.

Platforms are ideal for problem-solving — and bringing together stakeholders who have traditionally been in conflict with one another — because they share the same data between all parties, so each side is making decisions with the same information. This creates a shared source of truth and brings disparate parties to the same page, removing some of the skepticism and even rebuilding trust.

As the benefits of stakeholder-supporting platforms become evident across many areas of healthcare, one area that’s ripe for innovation is drug pricing. Here, the consequences of adversarial relationships have been especially evident, leading to waste, inefficiency, higher costs and protracted legal battles.

Much of this conflict has centered on the 340B Drug Pricing Program, in which manufacturers make prescription drugs available to eligible providers at deeply discounted prices. Providers use 340B program revenues to shore up slim operating margins, provide expanded services to their communities and make medicines more affordable for patients.

But tensions have risen in 340B, primarily due to a lack of transparency and trust between manufacturers, providers, pharmacies and payers over complex issues surrounding compliance and information exchange. These challenges have resulted in many safety net providers, particularly those who serve the most vulnerable populations, experiencing significant impacts on their revenue and operations. Legal remedies are in motion, but the process is slow and the outcome is uncertain. If these differences aren’t resolved, the impact could be profound.

While all 340B program stakeholders have good intentions, fragmented systems, outdated technology and failing infrastructure have hampered transparency, causing confusion and distrust. Manufacturers, providers, pharmacies and payers all have their own tracking, reporting and invoicing systems, so it’s easy for important indicators to get lost even when critical data is being exchanged between parties. This leads to mistakes that cause inaccurate payments.

Inaccurate payments are a growing problem. A conservative estimate is that at least 3-5% of 340B discounts are duplicated with Medicaid, something that is prohibited by the 340B statute. By 2019, these duplicate discounts amounted to anywhere from $933 million to $1.6 billion a year or higher.

The issue is especially significant at contract pharmacies, of which close to 30,000 now partner with providers to dispense drugs purchased at discounted 340B prices to eligible patients. These arrangements enable providers to take full advantage of the benefits of 340B, and even more importantly, expand patient access to needed medicines. However, the lack of transparency surrounding these dispenses is a concern for manufacturers, a handful of whom have chosen to take actions to limit contract pharmacy participation, creating grave concerns for providers, along with significant financial impacts. 

An aging infrastructure creates obstacles to compliance and makes participation in the program more challenging, degrading trust and increasing antagonism in relationships between stakeholders who should be working together for the good of patients.

But as a platform provides more compatibility, communications can become more direct, resolving uncertainties. In the case of 340B, greater visibility would give manufacturers insight into the business impact of non-compliant discounts; and, from the provider end, they could better manage their own compliance programs with limited resources, freeing up more resources to better care for patients. 

Platform technology has already made an impact in many areas of healthcare. With a platform’s ability to bring stakeholders together, comes new opportunities for transparency and collaboration that are deeply needed in the drug cost ecosystem.


About David de Vogel

Dave is a founder and the Chief Technology Officer at Kalderos, a company delivering technology that solves the challenges facing the US healthcare system. He’s a software development professional who’s been designing, architecting and building innovative software systems for more than twenty years. Dave is passionate about technology and driven by the challenge and adventure of finding and implementing the most appropriate solutions for bringing Kalderos’ business value to market.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Drug-Pricing Transparency

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |